Results of a phase II randomized trial of docetaxel, estramustine and prednisone- two schedules- verus mitoxantrone and prednisone in patients with hormone refractory prostate cancer. - Oudard,S.; Banu,E.; Voog,E. (Eur Urol, 2003)